Breaking Biotech
Breaking Biotech

Oct 10, 2026 · 25 min

Listen from 11:37

Listen at 11:37

Biotech ETFs frame a week of company-specific moves

118 - End of Week Wrap up - Oct 9, 2026

The episode places coverage of Moderna, Caribou, and Lilly alongside broad market benchmarks to show how biotech performed during the week ending October 9.

3 key takeaways
  1. 1Major market indices provide the backdrop for the week’s biotech performance review.
  2. 2The wrap-up highlights Moderna, Caribou, and Lilly among the episode’s company-specific stories.
  3. 3Biotech-focused ETFs including XBI, ArcG, and IBB anchor the sector comparison.

Don't miss

The episode shifts from broad market benchmarks to company-level coverage of Moderna, Caribou, and Lilly.

The brief

Matthew Cloutier opens the October 9 end-of-week edition by setting up a review of major market indices, biotech benchmarks, and the sector stories that shaped the week.

The market frame includes SPX, Q's, and IWM, alongside biotech-focused funds XBI, ArcG, and IBB, giving the episode a broad-to-narrow view of performance.

Company coverage turns to Moderna and its MRNA ticker, Caribou, and Lilly, linking individual biotech stories to the wider market backdrop.

The episode’s central value is comparison: it treats biotech performance not as an isolated story, but as a sector movement measured against broader indices.

What was said on this episode

33 statements · 14 positive · 10 negative · 2 mixed · 7 neutral

  1. Matthew Cloutieron SPXPositive0:38

    The SPX rose 1.16% during the week ending October 9.

    “The SPX certainly had a great week this week, up 1.16%.”

    Listen at 0:38

  2. Matthew Cloutieron IWM and XBINegative0:48

    IWM and XBI declined during the week ending October 9.

    “We saw a decline in the small caps, IWM, as well as the XBI.”

    Listen at 0:48

  3. Matthew Cloutieron Bio-AI tradePositive2:24

    The bio-AI trade may return to its prior extreme activity.

    “there's some speculation that we're going to go back to craziness when it comes to the bio AI trade”

    Listen at 2:24

  4. Caribou pursued an allogeneic CAR-T method using donor-derived cells.

    “Caribou Biosciences wanted to do was come up with an allogenic method.”

    Listen at 4:39

  5. Caribou lacked a competitive differentiator versus other allogeneic cell-therapy companies.

    “Caribou really didn't have a differentiator that made them more competitive than these other companies.”

    Listen at 5:29

  6. Caribou failed to attract sufficient investor support for its clinical strategy.

    “they weren't able to get investors to buy into the concept”

    Listen at 5:40

  7. A more experienced CEO might have helped Caribou’s clinical efforts.

    “maybe if a ceo had been chosen that had a little bit more experience in the space it might have been helpful”

    Listen at 6:06

  8. Matthew Cloutieron Biotech clinical indication selectionPositive6:38

    Biotech companies should choose clinical indications that improve on existing technologies.

    “choosing the right indications to go into”

    Listen at 6:38

  9. Caribou reached a peak valuation of $1.8 billion in September 2021.

    “they were at $1.8 billion in September of 2021”

    Listen at 6:57

  10. Eli Lilly may pursue MASH because it lacks liver-fibrosis expertise.

    “an area where they might want to get into might be something like MASH”

    Listen at 10:36

  11. Eli Lilly’s next acquisition is uncertain.

    “it's anyone's guess who lily is going to acquire next”

    Listen at 11:12

  12. Viking is not among Matthew’s leading candidates for Lilly acquisition.

    “it doesn't seem like Viking would be on my high list”

    Listen at 11:37

  13. Matthew Cloutieron Moderna melanoma vaccine dataMixed15:13

    Moderna’s October 24 melanoma data will materially move its stock.

    “it's definitely going to be a mover for the stock if it's going to be good or bad”

    Listen at 15:13

  14. Matthew Cloutieron ModernaPositive16:18

    Moderna’s valuation rose from $25 billion to approximately $90 billion.

    “they went from a 25 billion dollar valuation to about 60 billion immediately after and then now they're trading at about a 90 billion dollar valuation”

    Listen at 16:18

  15. Matthew Cloutieron Moderna melanoma drugNegative16:31

    The melanoma drug’s annual peak sales may be below $3 billion.

    “some of the expected valuations i've seen or at least the peak sales of the melanoma drug for the specific population they're looking at Some people are saying maybe $3 billion annually, probably not even that high”

    Listen at 16:31

  16. Matthew Cloutieron Moderna melanoma drugNeutral16:41

    Analysts estimate annual peak sales for Moderna’s melanoma drug below $3 billion.

    “Some people are saying maybe $3 billion annually, probably not even that high”

    Listen at 16:41

  17. Matthew Cloutieron ModernaNegative16:54

    Moderna’s market-cap increase appears disproportionate to expected melanoma-drug sales.

    “how is that leading to an additional $60 billion in market cap for this company? It just doesn't make sense.”

    Listen at 16:54

  18. Matthew Cloutieron ModernaNegative17:24

    Matthew advises against shorting Moderna.

    “I would not want to be shorting this”

    Listen at 17:24

  19. Matthew Cloutieron Moderna kidney cancer therapyNeutral18:33

    Moderna is expected to present kidney-cancer therapy data in the first half of 2027.

    “in H1 of 2027, they're going to be showing some data of a similar therapy in a kidney cancer indication”

    Listen at 18:33

  20. Matthew Cloutieron Moderna personalized cancer vaccineMixed18:43

    Moderna’s personalized vaccine may or may not work in kidney cancer.

    “Is melanoma a one-off or can it work also in a kidney cancer setting?”

    Listen at 18:43

  21. Matthew Cloutieron ModernaNegative19:09

    Failure in Moderna’s NSCLC trials could sharply reduce its valuation or expectations.

    “a failure there could really help smack the company with reality”

    Listen at 19:09

  22. Matthew Cloutieron Moderna melanoma vaccine dataPositive19:19

    Strong October 24 data could push Moderna to further all-time highs.

    “if the data looks particularly good on october 24th it's going to continue to reach those all-time highs”

    Listen at 19:19

  23. Matthew Cloutieron AbivaxPositive20:09

    Abivax may be a better buy around the mid-80s than at 140.

    “I think maybe now that the stock has settled around the mid 80s or so, it's probably a better time to buy now than obviously when it was in 140.”

    Listen at 20:09

  24. Matthew Cloutieron Biotech M&ANeutral20:22

    Biotech M&A processes generally take a long time and require patience.

    “I think M&A takes a long time and you need to be patient with it.”

    Listen at 20:22

  25. Matthew Cloutieron Biotech M&ANeutral20:22

    Biotech M&A generally requires patience because transactions take a long time.

    “M&A takes a long time and you need to be patient with it”

    Listen at 20:22

  26. Matthew Cloutieron Economic nationalism and biotech transactionsNegative20:57

    Increasing economic nationalism may create obstacles for biotech transactions.

    “a lot of countries being a little bit more nationalistic in the way that they do commerce, I think it might put up roadblocks”

    Listen at 20:57

  27. Matthew Cloutieron Retail-driven biotech stocksPositive22:14

    Investors who tolerate retail-driven biotech volatility may achieve strong returns.

    “if you can stomach through that, you can do really well”

    Listen at 22:14

  28. Matthew Cloutieron Biotech investingNegative22:19

    Biotech investors should cut losses when their thesis changes.

    “you have to cut your losses”

    Listen at 22:19

  29. Matthew Cloutieron Biotech investingPositive22:23

    Taking profits in biotech is generally a sound strategy.

    “taking profits when you have them. is never a way to go wrong”

    Listen at 22:23

  30. Nektar’s sharp pullback appears unjustified and may present an opportunity.

    “Nektar, what has really changed? I don't know. I don't really get why the pullback was so dramatic, but I think it's an opportunity.”

    Listen at 23:38

  31. Inventiva is Matthew Cloutier’s next MASH investment candidate to investigate.

    “I think the MASH play I'm going to look at next is IVA.”

    Listen at 23:53

  32. Matthew Cloutieron Inventiva pan-PPAR agonistPositive24:01

    Inventiva’s pan-PPAR agonist has a good chance of succeeding in Phase 3.

    “they have a pan ppar agonist that i think you know i think it's got a good chance of succeeding in phase three”

    Listen at 24:01

  33. Matthew Cloutieron Inventiva pan-PPAR agonistPositive24:04

    Inventiva’s pan-PPAR agonist has a good chance of succeeding in phase 3.

    “I think it's got a good chance of succeeding in phase three”

    Listen at 24:04

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Weekly email

State of the Pod, every Monday

The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.

Listen to the full episode and explore every guest, topic, and moment on PodLume.